Antiviral therapy in HCV-infected decompensated cirrhotics
Authors:
Open Access
- 1 January 2010
- journal article
- review article
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 16 (4) , 310-4
Abstract
Decompensated cirrhosis has traditionally been considered a contraindication to interferon and ribavirin therapy. Whereas, the same may be true for advanced cirrhosis, which is only successfully amenable to liver transplantation (LT), there are reports in the literature in which antiviral therapy was given successfully in selected cases of early hepatic decompensation with an aim to attain sustained viral clearance, halt disease progression, and expect potential (though, often, partial) recovery of hepatic metabolic activity. Antiviral therapy may also be instituted to prevent hepatitis C recurrence after LT (it has even caused removal of some patients from the waiting list for LT). Thus, decompensation per se is no more an absolute contraindication to antiviral therapy. Nonetheless, considering that a large proportion of such patients have pre-existing hematological cytopenias, modifications in antiviral dose regimens and close monitoring is required in order to prevent worsening of the same. Although the final sustained virological response rates attained in these patients are relatively low, successful antiviral therapy is potentially lifesaving which explains the need to go for it. In this article, the pros and cons of antiviral therapy in decompensated liver cirrhosis are reviewed with special emphasis on how to avoid antiviral dose reductions/withdrawals secondary to the development of hematologic side effects by using hematopoietic growth factors.Keywords
This publication has 30 references indexed in Scilit:
- Safety, tolerability, and efficacy of pegylated‐interferon alfa‐2a plus ribavirin in HCV‐related decompensated cirrhoticsAlimentary Pharmacology & Therapeutics, 2008
- Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated conditionWorld Journal of Gastroenterology, 2008
- Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patientsSaudi Journal of Gastroenterology, 2008
- Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled studyJournal of Hepatology, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Treating hepatitis C infection in liver transplant recipientsLiver Transplantation, 2006
- Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantationJournal of Hepatology, 2003
- Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patientsSupportive Care in Cancer, 2002
- Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type CJournal of Hepatology, 1997
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987